

Supplementary Figures and Tables

Serum MicroRNA Reflects Injury Severity in a Large Animal Model of Thoracic Spinal Cord Injury

Seth Tigchelaar¹, Femke Streijger¹, Sunita Sinha², Stephane Flibotte², Neda Manouchehri¹, Kitty So¹, Katelyn Shortt¹, Elena Okon¹, Michael Rizzuto¹, Ivana Malenica³, Amanda Courtright³, Andrew Eisen⁴, Kendall Van Keuren-Jensen³, Corey Nislow², Brian K. Kwon^{1,5,*}

¹International Collaboration on Repair Discoveries (ICORD), University of British Columbia, Vancouver, British Columbia, Canada;

²Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada;

³Translational Genomics, Phoenix, Arizona, United States of America;

⁴Acorda Therapeutics, Ardsley, New York, United States of America;

⁵ Vancouver Spine Surgery Institute, Department of Orthopedics, University of British Columbia, Vancouver, British Columbia, Canada

*** Corresponding Author (and for Reprints):**

Brian K. Kwon, MD, PhD, FRCSC

Canada Research Chair in Spinal Cord Injury

Professor, Department of Orthopaedics, University of British Columbia

6th Floor, Blusson Spinal Cord Centre, Vancouver General Hospital

818 West 10th Avenue, Vancouver, BC, CANADA, V5Z 1M9

PH: 604-875-5857

FX: 604-875-8223

E-mail: brian.kwon@ubc.ca


Seth Tigchelaar	s.tigchelaar@alumni.ubc.ca	Ph: 604-675-8837, Fax: 604-675-8849
-----------------	----------------------------	-------------------------------------

Femke Streijger	streijger@icord.org	Ph: 604-675-8837, Fax: 604-675-8849
Sunita Sinha	Sunita.sinha@ubc.ca	Ph: 604-827-0310, Fax: 604-675-8849
Stephane Flibotte	sflibotte@gmail.com	Ph: 604-827-0310, Fax: 604-675-8849
Neda Manouchehri	nedamanouchehri@gmail.com	Ph: 604-675-8837, Fax: 604-675-8849
Kitty So	Kitty.ubc@gmail.com	Ph: 604-675-8837, Fax: 604-675-8849
Katelyn Shortt	Katelyn.shortt@gmail.com	Ph: 604-675-8837, Fax: 604-675-8849
Elena Okon	okon@icord.org	Ph: 604-675-8837, Fax: 604-675-8849
Michael Rizzuto	Michael.rizzuto@alumni.ubc.ca	Ph: 604-675-8837, Fax: 604-675-8849
Ivana Malenica	imalenica@tgen.org	Ph: 602-343-8400, Fax: 602-343-8411
Amanda Courtright	acourtright@tgen.org	Ph: 602-343-8400, Fax: 602-343-8411
Andrew Eisen	aeisen@acorda.com	Ph: 914-326-5058, Fax: 914-606-9634
Kendall Van Keuren-Jensen	kjensen@tgen.org	Ph: 602-343-8400, Fax: 602-343-8411
Corey Nislow	corey.nislow@ubc.ca	Ph: 604-827-0310, Fax: 604-675-8849
*Brian K. Kwon	brian.kwon@ubc.ca	Ph: 604-875-5857, Fax: 604-875-8223


Supplementary Table 1. Novel miRNA. To be listed, the potential miRNA must be present in at least 30% of either Serum or CSF samples, and have more than 5 counts on average across all samples. Column one through three contains the location of the sequence predicted by miRDeep2 for the potential mature miRNA. Column four is the percentage of serum samples in which the miRNA was detected and column five is the percentage of CSF samples in which the miRNA was detected. Column six represents the total percentage of samples in which the miRNA was detected.

miRNA Location			Mature Sequence	% of serum Samples	% of CSF Samples	% of Total Samples
Chr	Start	Stop				
chr15	133957559	133957616	gcgacgagccccucgcacaaaccggaccugagcguuuugucguucggcucgcguga	76.53	50.00	71.31
chr6	870006	870063	cgguccgggucggggcggggcgagcuuccucagugcggccggcgggucgcgccc	75.51	50.00	70.49
chrX	39824716	39824776	gccaguuacuuccgcucugaugggaucuaauuuccauuuacgagcggcgagcucugaac	71.43	45.83	66.39
chr12	37079098	37079158	gcuucgacuuuuugcacuacugacuauuacagcugagcagugcaauaguuuuuagaaagc	71.43	41.67	65.57
chr5	66193719	66193780	ucuccagcacaguguggauggucuaauagugaagcuccuaaacacugucuguaaagaug	67.35	50.00	63.93
chr13	24885255	24885316	uucaaguaaccaggauaggcugcagggucccaaggggccuaauucuuugguuacuugcacg	68.37	41.67	63.11
chr10	6017465	6017551	guccgagguagugguuauacagaacuuauuaacguuagucucuaaaguuugguauacaaccccc ccacugcuaaaauugacug	64.29	50.00	61.48
chrX	48640827	48640885	uaccuauugcauuacggaguuuguaauucucuaaagcaccuccuaugugcaugguuuac	57.14	33.33	52.46
chr16	51742262	51742327	gcagagucaagccuguuagcacuuggaugggagaccgucugggcauaccgggucgugaggcuu	55.10	25.00	49.18
chr7	55687381	55687443	ucugguucugugaccucgcuauuuugccuucagccagguuaagagcaucugaaccagggggu	46.94	16.67	40.98
chr5	30185306	30185368	gugccugguucccucccagagguucaaaauuaauugcucugagauugaccuaggcaucc	38.78	37.50	38.52
chr3	42401527	42401607	cugaugggcggggcaacgugagggcagccagcaccugugagguuugguugcugacguuggcucu ggagggucggcu	39.80	25.00	36.89
chr7	69920245	69920312	cgcgccggggggcgccggaggguccacugagcucucccccacccucccgccucucucgccc	37.76	25.00	35.25
chr10	50066936	50066995	ggcgggcccacggggccccccgugagcccggcccgccggccccguggccccccgg	30.61	37.50	31.97
chr12	35722001	35722067	cccuugaugaucuuuccucucucugguugagagagggcagagggagagaacaccgucugaguggu	27.55	33.33	28.69


Supplementary Figure 1. Spearman Correlation (green) of subsets of randomly selected reads to a total of 1.7 million reads, starting with 1,000 reads and incrementally increasing by thousands to 300,000. Number of miRNA detected (blue) using randomly selected reads, starting with 1,000 reads and incrementally increasing by thousands to 300,000.



Supplemental Figure 2. Correlation of serum and CSF miRNA counts for all detected genes.




Supplementary Figure 3. Effect of Injury Severity on Global miRNA Expression. Raw data showing the global miRNA expression at BSL, 1, 3, and 5 dpi in each of the A. 40 cm, B. 20 cm, C. 10 cm, and D. SHAM groups. Datapoints represent the average read counts for the top 100 miRNA genes for n=4 animals per group and time point (see Table 1).




miR-144			2.93 *					
miR-145-3p	1.82 *							
miR-145-5p	1.89 **							
miR-1468					1.31 **			1.39 ***
miR-148b-3p		3.24 *	3.20 *					
miR-149	1.41 **	1.41 **	1.34 **					
miR-150		1.47 **	1.49 *					
miR-152		1.63 **	1.51 *					
miR-15a	2.10 *	1.96 *	2.01 **					
miR-204	6.38 **							
miR-208b	5.85 ***	3.33 ***		5.50 ***		4.85 **	7.43 **	
miR-216	3.67 ***							
miR-22-3p	1.18 *	1.16 *		1.21 **				
miR-22-5p	3.26 **	3.20 **	2.57 **					
miR-221-3p		1.43 ***	1.42 **					
miR-222		1.67 **	1.73 **					
miR-23b		3.27 *	3.10 **					
miR-26a		1.55 *	1.53 *					
miR-27a	1.50 *	1.41 *						
miR-27b-3p	1.29 *			1.20 **	1.11 **			
miR-29c	4.24 *							
miR-301		2.33 **	2.30 **					
miR-30a-3p					1.33 **			
miR-30a-5p				1.18 *	1.17 **			
miR-30b-5p		1.60 *						
miR-365-3p	2.78 *			1.59 *	1.57 *	1.48 ***		
miR-378	1.46 **	1.39 **	1.24 *	1.51 ***	1.40 **	1.32 **	1.37 ***	
miR-378b-3p	2.26 **	2.43 ***	1.96 **	2.43 **	2.38 **			2.26 **
miR-423-3p		1.12 *						
miR-425-3p		2.08 *						
miR-425-5p		1.31 *	1.28 **					
miR-4331	0.79 **	0.78 *	0.63 **					
miR-450b-5p	2.30 ***							

miR-451		1.36 *	1.32 *					
miR-486		1.17 *			1.19 **			
miR-574	1.51 **	1.48 ***	1.46 **					
miR-7134-3p		1.56 *	1.57 **					
miR-7139-5p			1.65 **		1.64 *			
miR-744			1.35 *					
miR-885-5p	8.09 **	6.50 *						
miR-98		1.86 *	1.81 *					
miR-9841-3p		1.78 **	1.73 **					
Total	27	42	37	16	16	9	5	2

Supplementary Figure 4. Correlations between total miRNA expression and Porcine Thoracic Injury Behaviour Scores. Correlation between 12 wpi PTIBS scores and the total miRNA counts at **A.** Baseline before injury (BSL), **B.** 1 dpi, **C.** 3 dpi, and **D.** 5 dpi. The global upregulation in miRNA at 1 and 3 dpi is correlated strongly with the behavioral recovery at 12 weeks post-injury.



Supplementary Figure 5. Correlations between total miRNA expression levels and total percent spared tissue. Correlation between total percent spared tissue and the total miRNA counts at **A.** baseline before injury (BSL), **B.** 1 day post-injury (dpi), **C.** 3 dpi, and **D.** 5 dpi. The global upregulation in miRNA is correlated strongly with the extent of tissue damage at 1 and 3 dpi in particular.



Supplementary Figure 6. Correlation between Force of Injury (N) and outcome parameters. Correlation between Force of injury and **A.** Porcine Thoracic Injury Behaviour Scores at 12 wpi and **B.** Total percent spared tissue. These figures simply demonstrate that for our pig model of thoracic SCI, the initial force of the contusion impact (dictated by the height of the weight drop) is strongly correlated to the degree of hindlimb locomotor impairment as measured by PTIBS (**A**) and the amount of tissue damage that occurs in the spinal cord (**B**).

